MED12在中东结直肠癌中反复突变
该研究对27例沙特结直肠癌患者行全基因组测序,发现3个MED12体细胞突变,并在400例患者中通过二代测序确认MED12反复突变富集。细胞系实验显示MED12表达与TGF-β信号负相关、与化疗后凋亡正相关,实验操纵MED12表达可重现这些相关性。
要点
- 全基因组测序发现27例结直肠癌中3个MED12体细胞突变。
- 400例结直肠癌二代测序确认MED12反复突变富集。
- MED12表达与TGF-β信号负相关、与化疗后凋亡正相关。
核心结论
- 数据将MED12在其他癌症中作为抑癌基因的作用扩展至结直肠癌,并提示TGF-β信号可能是该效应的潜在介质。
研究设计与样本
- 发现阶段对27例沙特结直肠癌患者行肿瘤与对应胚系DNA全基因组测序。
- 复制阶段采用二代测序方法在400例结直肠癌患者中捕获并测序MED12及其他候选基因。
- 体外研究使用MED12表达水平差异显著的结直肠癌细胞系,并通过实验操纵MED12表达。
主要发现
- 发现阶段除已知驱动突变外,鉴定出3个MED12体细胞突变。
- 复制阶段在400例患者中确认MED12反复突变富集。
- MED12表达水平与转化生长因子(TGF)-β信号呈负相关。
- MED12表达水平与化疗药物应答中的凋亡呈正相关。
- 实验操纵MED12表达后这些相关性被重现。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Colorectal cancer (CRC) is a common cancer and a leading cause of cancer deaths. Previous studies have identified a number of key steps in the evolution of CRC but our knowledge of driver mutations in CRC remains incomplete. Recognising the potential of studying different human populations to reveal novel insights in disease pathogenesis, we conducted genomic analysis of CRC in Saudi patients. DESIGN: In the discovery phase of the study, we conducted whole genome sequencing of tumour and corresponding germline DNA in 27 patients with CRC. In addition to known driver mutations, we identified three MED12 somatic mutations. In the replication phase, we employed a next-generation sequencing approach to capture and sequence MED12 and other candidate genes in a larger sample of 400 patients with CRC and confirmed the enrichment for recurrent MED12 mutations. RESULTS: In order to gain insight into a plausible biological mechanism for the potential role of MED12 mutations in CRC, we studied CRC cell lines that differ substantially in the expression level of MED12, and found the latter to be correlated inversely with transforming growth factor (TGF)-β signalling and directly with apoptosis in response to chemotherapeutic agents. Importantly, these correlations were replicated when MED12 expression was experimentally manipulated. CONCLUSIONS: Our data expand the recently described role of MED12 as a tumour suppressor in other cancers to include CRC, and suggest TGF-β signalling as a potential mediator of this effect.
引用
- Siraj AK, Masoodi T, Bu R, et al. MED12 is recurrently mutated in Middle Eastern colorectal cancer. Gut. 2017. PMID: 28183795. doi:10.1136/gutjnl-2016-313334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。